Skip to main content

Table 1 Patient demographics and baseline characteristics of randomized patients.

From: Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

  T/HCTZ (n = 428) V/HCTZ (n = 412)
Gender (n [%])   
   Men 230 (53.7) 239 (58.0)
   Women 198 (46.3) 173 (42.0)
Age   
   Mean ± SD (years) 58.5 ± 9.7 59.2 ± 9.7
   ≥ 65 years (n [%]) 122 (28.5) 119 (28.9)
Race (n [%])   
   White 292 (68.2) 292 (70.9)
   Black 61 (14.3) 59 (14.3)
   Asian 75 (17.5) 61 (14.8)
BMI   
   Mean ± SD (kg/m2) 33.6 ± 5.7 33.4 ± 5.3
Hypertension duration   
   Mean ± SD (years) 9.2 ± 9.5 8.9 ± 9.2
24-hour ABP   
   Mean SBP ± SD (mm Hg) 148.0 ± 11.9 147.8 ± 12.4
   Mean DBP ± SD (mm Hg) 83.1 ± 9.2 83.3 ± 10.2
Trough seated BP   
   Mean SBP ± SD (mm Hg) 156.8 ± 12.5 157.1 ± 12.3
   Mean DBP ± SD (mm Hg) 92.1 ± 9.3 91.7 ± 9.8
HbA1c (%)   
   Mean ± SD 7.0 ± 1.1 7.2 ± 1.2
  1. ABP: ambulatory blood pressure; DBP: diastolic blood pressure; T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ; valsartan 160 mg plus HCTZ 12.5 mg; SBP: systolic blood pressure.